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PURPOSE: To evaluate percutaneous cryotherapy as a primary treatment option for high-risk prostate cancer patients.
PATIENTS AND METHODS: From October 2000 to February 2005, 21 high-risk (Gleason e•8 and/or PSA > 10 and/or stage >
T2a) prostate cancer patients underwent 24 percutaneous prostate cryoablation procedures. Patients’ median age was 70.9, and
the average pretreatment PSA was 19.5 ng/dL. The follow-up period ranged from 6 to 60 months (median, 41 months).
RESULTS: The PSA failure rate was 39%, 52.9%, and 42.8% at 12, 24, and 60 months of follow-up, respectively. Overall
complication rates were low, with 8% of urinary incontinence and no cases of rectal injury; however, 96% of erectile dysfunction
occurred. The cryoablation procedure failed in 12 patients (57.2%); 7 (58.3%) of these were local failures (positive prostate
biopsies).
CONCLUSION: Percutaneous cryoablation of the prostate is a safe minimally invasive treatment, but it has poor PSA-free
survival outcomes in high-risk prostate cancer patients.
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INTRODUCTION
Cryoablation is an alternative treatment modality for
prostate cancer that destroys tumoral and prostate gland tis-
sue. It was initially introduced in the 1960s by Gonder et
al1, but it was later abandoned because of the high com-
plication rate due to the inability to control the freezing
process, causing rectal injury and urethral obstruction.2
Only in the 1990s, with the introduction by Gary Onik of
a real-time ultrasound visualization associated with tem-
perature sensors3, has cryotherapy become a safer and ac-
ceptable option for treatment of prostate cancer patients.
The procedure allows better control of the “ice ball,” avoid-
ing lesions to the surrounding tissue, urinary sphincter, and
rectum wall. Many centers around the world are gaining
experience in this relatively new procedure, with promis-
ing results.
High-risk prostate cancer treatment is still a challenge,
since most patients develop early recurrence regardless of
the treatment modality. Therefore, new modalities, or even
combined treatments, have been tested, in attempts to de-
velop a treatment with better recurrence-free survival.
The purpose of this study was to evaluate the treatment
of high-risk prostate cancer with cryoablation.
PATIENTS AND METHODS
Between October 2000 and February 2005, 24 proce-
dures with 3 reapplications were performed on 21 patients.
Patients’ ages ranged from 55 to 83 years (average, 70.9),
with an average pretreatment PSA of 19.5 ng/dL (range,
4.1 - 56 ng/dL). Gleason scores ranged from 4 to 9 (aver-
age, 7), and prostate weight ranged from 15 to 50 grams
(average, 26.6 grams). Clinical stage distribution was, 10
patients, T2NxMx and 14 patients, T3NxMx. Designation
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of high-risk prostate cancer was based on Gleason e•8, PSA
> 10. and clinical stage > T2a.
Patients with PSA levels over 30 ng/dL had previously
undergone laparoscopic lymph node dissection and were
considered for prostate cryoablation only after the nodes
were found negative (4 patients). All patients had negative
preoperative bone scans for metastatic disease.
Patients were evaluated regarding voiding symptoms
and erectile function, being considered impotent when they
were unable to perform sexual intercourse due to weak pe-
nile rigidity.
All patients received a rectal enema the night before
the procedure. Under spinal anesthesia, patients were
placed in a lithotomy position. Cystoscopy was under-
taken, and a supra-pubic bladder catheter was placed un-
der direct vision. All procedures were performed accord-
ing to the modified Onik technique using a CRYOCare
unit with argonium and helium gas for the freezing and
thawing, respectively, for a total of 2 freezing-thawing
cycles. Under transrectal ultrasound guidance, 5 to 7
cryoprobes were introduced into the prostate, and 4
thermoprobes were located bilaterally in the neurovascu-
lar bundles, one in the Denonvilliers’ fascia and the other
at the sphincter.
The freezing process was monitored in real time by
transrectal ultrasound and thermo probes for direct visu-
alization of the ice ball and to avoid lesions to adjacent
tissues. During the procedure, the urethra was protected
with a warming device at 37°C degrees that was kept in
place until the patients left the operating room. All patients
were discharged within 24 hours, with the suprapubic cath-
eter removed after a week.
Follow-up was undertaken at 3, 6, and 12 months and
annually thereafter in all cases, with clinical evaluation of
urinary outflow, continence (number of pads, and erectile
dysfunction, followed by digital rectal examination, urine
analysis, and PSA measurements. The follow-up period
ranged from 18 to 60 months (median, 41 months). Uri-
nary incontinence was defined as the need for pads.
Patients who did not reach a PSA nadir of 1 ng/dL or
less underwent prostatic biopsy followed by a bone scan
to evaluate the possibility of local or distant recurrence.
Patients with local recurrence only (PSA > 1 ng/mL, nega-
tive bone scan, and positive biopsy), underwent an addi-
tional cryoablation procedure (reapplication).
RESULTS
The PSA failure rate was 39% and 52.9%, respectively,
at 12 and 24 months of follow-up, with an average post-
treatment PSA of 8.68 and 12.3 ng/dL, respectively. At the
60-month follow-up, 42.8% of the patients were free of
PSA relapse (Figure 1).
Radical prostatectomy was not performed in 14 patients
due to severe comorbidities: 4 patients with previous acute
myocardial infarction, 1 patient with cardiac arrhythmia,
and 8 patients with severe diabetes mellitus.
Of the 13 (57%) of patients for which the cryoablation
procedure failed, only 6 (47%) had biopsy-proven local re-
currence with negative bone scan; 3 of these were treated
with a reapplication of cryoablation. The other 3 patients,
having no evidence of local recurrence (negative prostate
biopsy), were treated with hormonal blockade only
(Figure 2).
Complications were mostly minor, with 19% of mild
hematuria and 13% of perineal/scrotum hematoma with no
need for further treatment. There was no case of rectal in-
jury, nor any need for blood transfusion. Urgency during
the first 6 months of follow-up occurred in 23% of patients
and was adequately managed with anticolinergic medica-
tions. Of the 14 previously potent patients, erectile dysfunc-
tion was found in 13 (93%).
Urinary incontinence, defined as the need for 1 or more
pads a day, was present in 12% of patients. One patient
Figure 1 - Kaplan Mayer curve showing recurrence based on PSA for 21
high-risk prostate cancer patients
Figure 2 – PSA values in 21 high-risk prostate cancer patients after 6, 12,
24, and 48 months of treatment with cryoablation
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had a severe posterior urethral necrosis due to warming
catheter malfunction during the freezing process. Urethral
obstruction from prostate tissue sloughing occurred in 2
cases (8%), which was treated by transurethral resection
of the necrotic tissue.
DISCUSSION
In spite of the evolution of diagnostic methods, the
prevalence of locally advanced or metastatic prostate can-
cer remains high, and some authors state that 20% of the
prostate cancer cases are diagnosed with a high-risk pres-
entation. The high-risk group of patients comprises a wide
spectrum of disease, ranging from patients with aggressive
localized disease to those with widespread occult distant
metastases. Treatment of high-risk prostate cancer is still
a challenge since the recurrence rate, regardless of the treat-
ment modality, remains high.4,5
Multimodal treatment has been proposed for this sub-
group, with assorted morbidities and oncologic results, such
as radical prostatectomy associated with neoadjuvant hor-
mone therapy or conformal radiotherapy associated with
long-term hormone therapy.5,6
Prostate cryoablation, a minimally invasive treatment
with low complication rates, has been proposed as a less
invasive alternative treatment.7 However, when cryoablation
is compared with radiotherapy, a noninvasive treatment, this
advantage becomes less evident. Neverthless, high feasi-
bility rates and the prompt return to regular life activities
make cryoablation an attractive treatment.
Donnelly et al8 found 48% biochemical recurrence in
high-risk patients treated exclusively by prostate
cryoablation at the 5-year follow-up. Bahn et al,9 using a
PSA-based definition of biochemical failure of 0.5 ng/mL,
found a recurrence-free rate of 39% at the 7-year follow-
up in high-risk patients.9
In a recent study, Prepelica et al10 performed
cryoablation as the primary therapy for 65 high-risk pros-
tate cancer patients (PSA over 10 ng/dL or Gleason 8 or
higher) with a median follow-up of 35 months, finding du-
rable PSA biochemical disease-free survival in about 83.3%
of the patients according to the American Society for Thera-
peutic Radiology and Oncology (ASTRO) criteria.
In this study, we obtained a 61% and 47% biochemi-
cal-free survival rate at 12 and 24 months of follow-up, re-
spectively, for patients treated exclusively with prostate
cryoablation. At the 5-year follow up, 43% of the patients
were free of recurrence.
Stokes et al11 compared the long-term biochemical dis-
ease-free survival for patients undergoing radical prostate-
ctomy, transperineal ultrasound-guided iodine-125 implan-
tation, or external beam irradiation alone; the study was
performed in patients stratified based on PSA, Gleason
score, and staging. At 12 months of follow-up, only 40%
of the patients undergoing external beam radiation and 51%
undergoing seed implantation achieved PSA nadir < 1 ng/
mL. In a multi-institutional review by Fiveash et al12of 180
patients with high-grade prostate cancer treated with 3D
conformal radiotherapy, the 5-year PSA recurrence-free
survival was 62.5%. This result was similar to the results
of Bahn et al9 for high-risk patients.
Sylvester et al13 have been studying the effect of exter-
nal beam radiotherapy in addition to brachytherapy, with
45% biochemical control at 10 years of followup, which
is similar to the radical prostatectomy results but with
shorter hospital stays and less morbidity.
Onik et al, treating unconfined prostate cancer, found
80% negative biopsies 6 months after cryoablation.14 In a
study from the University of California at San Francisco,
Shinohara et al15 treated 102 patients, with 61 patients hav-
ing locally advanced disease (T3 and T4), and no techni-
cal problems were found. Real-time ultrasound control of
freezing and monitoring techniques allowed a safe
cryoablation, even with extra-prostatic freezing.
The results from those studies show that the ideal treat-
ment for high-risk prostate cancer is still controversial, and
new modalities and technologies must be developed in or-
der to offer a better treatment with reduced morbidity for
this group of patients.
CONCLUSION
Prostate cryoablation is a minimally invasive treatment
with promising results, and perhaps if associated with hor-
monal therapy, resulting in low morbidity rates. It is a safe
procedure even for high-risk patients, with low complica-
tion rates. The oncologic results are still poor for this group
of patients, and new modalities of treatment must be sought.
RESUMO
Hayek ORE, Alfer Jr. W, Reggio E, Pompeo ACL, Arap S,
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OBJETIVO: Avaliar a crioterapia percutânea como
tratamento primário para o câncer de próstata de alto risco.
PACIENTES E MÉTODOS: De outubro de 2000 a
fevereiro de 2005, 21 pacientes com câncer de próstata de
alto risco foram submetidos a 24 crioablações de próstata
como tratamento primário. A mediana de idade dos
pacientes foi de 70,9, e a média do PSA pré-tratamento de
19,5 ng/dl. O tempo de seguimento variou de 6 a 60 meses
(mediana de 41 meses).
RESULTADOS: Os índices de falha do PSA foram de 39%
e 52,9% respectivamente aos 12 e 24 meses de seguimento.
A sobrevida livre de doença em 5 anos foi de 42,8%. De
maneira geral os índices de complicações foram baixos,
com 8% de incontinência urinária e nenhum caso de lesão
retal. Os índices de impotência foram de 96%. Em doze
pacientes (57,2%) onde houve falha da crioablação, 7
(58,3%) apresentaram recidivas locais (biópsia positiva) e
os demais recidiva a distância.
CONCLUSÃO: A crioablação percutânea da próstata é um
tratamento minimamente invasivo da próstata, seguro, porém
ainda com resultados modestos em pacientes com câncer de
próstata de alto risco, quando se considera a sobrevida livre
de doença em 5 anos, havendo portanto necessidade de
associação de outras modalidades terapêuticas no tratamento
deste grupo específico de doentes.
UNITERMOS: Câncer de próstata. Crioterapia.
Tratamento do câncer de próstata.
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